B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)
Goss, Glenwood, Ferry, David, Laurie, Scott, Wierzbicki, Rafal, Thompson, Joyce, Biesma, B, Duffield, Emma, Ghiorghiu, Serban, Zarenda, Marc, Armour, AlisonVolume:
2
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1097/01.JTO.0000283154.03863.ae
Date:
August, 2007
File:
PDF, 165 KB
english, 2007